Inclusion Criteria:

          1. CEA positive T4/N2 high-risk stage-Ⅲ colorectal cancer after surgery or patients with
             colorectal cancer liver metastasis after R0 surgery;

          2. Patients whose serum CEA ≥11 ng/mL;

          3. Life expectancy ≥ 3 months;

          4. PS score 0-2, KPS score ≥60;

          5. >3 CTC/7.5 mL blood sample;

          6. Patients who plan to use XELOX chemotherapy after surgery;

          7. Patients must have adequate organ function , such as NYHA heart function
             classification grade III or higher, no severe anemia, hypoxia; liver function: total
             bilirubin ≤ 1.5 × ULN (total bilirubin ≤ 3 × ULN when liver metastasis), ALT≤2.5×ULN,
             AST≤2.5×ULN (ALT or/and AST≤5×ULN when liver metastasis); renal function: blood
             creatinine ≤1.5 × ULN and creatinine clearance ≥50 mL/min, only when blood creatinine
             ≤ Calculate the creatinine clearance rate when 1.5 × ULN;

          8. Sufficient peripheral blood can be obtained through peripheral veins without
             contraindications to apheresis;

          9. Patients of childbearing age have no birth plans and take effective contraceptive
             measures during the study period and within 1 year after the study.

        Exclusion Criteria:

          1. Patients who have a history of severe central nervous system disease;

          2. Other organ metastases except liver;

          3. Patients who have non malignant diseases, including autoimmune diseases, primary
             immunodeficiency diseases or obstructive or restrictive respiratory diseases;

          4. Patients received car-t or other gene modified T cell therapy previously;

          5. Patients who plan to use other targeted anti-tumor drugs;

          6. Patients who participated in other clinical studies within 30 days before screening or
             planned to participate in other clinical studies during the study period;

          7. Patients who have syphilis or HIV / HBV / HCV / HPV / EBV / CMV infection ; HBV-DNA
             copy number ≥ 1 × 10 ^ 5 copies / ml is required for HBV seropositive patients;

          8. Patients who have uncontrollable systemic infectious diseases;

          9. Patients who have multiple malignant tumor;

         10. Patients who received or may need Chinese herbal medicine, systemic glucocorticoid or
             other immunosuppressants within 2 weeks before enrollment;

         11. Patient who are pregnancy and lactating;

         12. Patients who have severe gastroduodenal ulcer, ulcerative colitis and other intestinal
             inflammation;